241 related articles for article (PubMed ID: 36776306)
1. KNL1 is a prognostic and diagnostic biomarker related to immune infiltration in patients with uterine corpus endometrial carcinoma.
He K; Li J; Huang X; Zhao W; Wang K; Wang T; Chen J; Wang Z; Yi J; Zhao S; Zhao L
Front Oncol; 2023; 13():1090779. PubMed ID: 36776306
[TBL] [Abstract][Full Text] [Related]
2. KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma.
Zhang M; Liu Y; Hou S; Wang Y; Wang C; Yin Y; Chen X
Mol Omics; 2022 Jul; 18(6):506-519. PubMed ID: 35485290
[TBL] [Abstract][Full Text] [Related]
3. Development of a necroptosis-related prognostic model for uterine corpus endometrial carcinoma.
Zhang Q; Luo Y; Zhang S; Huang Q; Liu G
Sci Rep; 2024 Feb; 14(1):4257. PubMed ID: 38383747
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel key genes associated with uterine corpus endometrial carcinoma progression and prognosis.
Li H; Zhou Q; Wu Z; Lu X
Ann Transl Med; 2023 Jan; 11(2):100. PubMed ID: 36819577
[TBL] [Abstract][Full Text] [Related]
5. miR-149-3p Is a Potential Prognosis Biomarker and Correlated with Immune Infiltrates in Uterine Corpus Endometrial Carcinoma.
Lu X; Jing L; Liu S; Wang H; Chen B
Int J Endocrinol; 2022; 2022():5006123. PubMed ID: 35719192
[TBL] [Abstract][Full Text] [Related]
6. Identification and Validation of Cuproptosis-Related Prognostic Signature and Associated Regulatory Axis in Uterine Corpus Endometrial Carcinoma.
Chen Y
Front Genet; 2022; 13():912037. PubMed ID: 35937995
[No Abstract] [Full Text] [Related]
7. LHX1 as a potential biomarker regulates EMT induction and cellular behaviors in uterine corpus endometrial carcinoma.
Tian Y; Wen F; Wang S; Lv N
Clinics (Sao Paulo); 2022; 77():100103. PubMed ID: 36116266
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of PSAT1 inhibits cell proliferation and migration in uterine corpus endometrial carcinoma.
Wang M; Yue S; Yang Z
Sci Rep; 2023 Mar; 13(1):4081. PubMed ID: 36906716
[TBL] [Abstract][Full Text] [Related]
9. CXCL9 correlates with antitumor immunity and is predictive of a favorable prognosis in uterine corpus endometrial carcinoma.
Xue S; Su XM; Ke LN; Huang YG
Front Oncol; 2023; 13():1077780. PubMed ID: 36845675
[TBL] [Abstract][Full Text] [Related]
10.
Zhao Q; Chen G; Yang X; Wang T; Yuan S; Meng Q
Comb Chem High Throughput Screen; 2023; 26(2):330-338. PubMed ID: 35379118
[TBL] [Abstract][Full Text] [Related]
11. FAT2 mutation is associated with better prognosis and responsiveness to immunotherapy in uterine corpus endometrial carcinoma.
Wang Z; Xing L; Huang Y; Han P
Cancer Med; 2023 Feb; 12(3):3797-3811. PubMed ID: 36812126
[TBL] [Abstract][Full Text] [Related]
12. MCM10: An effective treatment target and a prognostic biomarker in patients with uterine corpus endometrial carcinoma.
Chen J; Wu S; Wang J; Han C; Zhao L; He K; Jia Y; Cui M
J Cell Mol Med; 2023 Jun; 27(12):1708-1724. PubMed ID: 37246638
[TBL] [Abstract][Full Text] [Related]
13. RNF183 Is a Prognostic Biomarker and Correlates With Tumor Purity, Immune Infiltrates in Uterine Corpus Endometrial Carcinoma.
Geng R; Zheng Y; Zhao L; Huang X; Qiang R; Zhang R; Guo X; Li R
Front Genet; 2020; 11():595733. PubMed ID: 33324448
[TBL] [Abstract][Full Text] [Related]
14. Tumor mutation burden in connection with immune-related survival in uterine corpus endometrial carcinoma.
Zhao L; Fu X; Han X; Yu Y; Ye Y; Gao J
Cancer Cell Int; 2021 Jan; 21(1):80. PubMed ID: 33509222
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive Analysis of ESRRA in Endometrial Cancer.
Wang S; Huo X
Technol Cancer Res Treat; 2021; 20():1533033821992083. PubMed ID: 33525981
[TBL] [Abstract][Full Text] [Related]
16. PPP1R14B is a diagnostic prognostic marker in patients with uterine corpus endometrial carcinoma.
He K; Wang T; Huang X; Yang Z; Wang Z; Zhang S; Sui X; Jiang J; Zhao L
J Cell Mol Med; 2023 Mar; 27(6):846-863. PubMed ID: 36824011
[TBL] [Abstract][Full Text] [Related]
17. TIMM8A is associated with dysfunction of immune cell in BRCA and UCEC for predicting anti-PD-L1 therapy efficacy.
Zhu X; Yuan Z; Cheng S; Wang H; Liao Y; Zhou D; Wu Z
World J Surg Oncol; 2022 Oct; 20(1):336. PubMed ID: 36207751
[TBL] [Abstract][Full Text] [Related]
18. Construction of a prognostic model of luteolin for endometrial carcinoma.
Zhao J; Jiao W; Sui X; Zou J; Wang J; Lin Z
Am J Transl Res; 2023; 15(3):2122-2139. PubMed ID: 37056832
[TBL] [Abstract][Full Text] [Related]
19. Identification of an immune gene signature for predicting the prognosis of patients with uterine corpus endometrial carcinoma.
Zhou C; Li C; Yan F; Zheng Y
Cancer Cell Int; 2020 Nov; 20(1):541. PubMed ID: 33292199
[TBL] [Abstract][Full Text] [Related]
20. Screening and validation of potential markers associated with uterine corpus endometrial carcinoma and polycystic ovary syndrome based on bioinformatics methods.
Wu R; Wu C; Zhu B; Li J; Zhao W
Front Mol Biosci; 2023; 10():1192313. PubMed ID: 37363398
[No Abstract] [Full Text] [Related]
[Next] [New Search]
